Analysts Set Expectations for TNGX FY2025 Earnings

Tango Therapeutics, Inc. (NASDAQ:TNGX) – Stock analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for shares of Tango Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt forecasts that the company will earn ($1.39) per share for the year. Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for Tango Therapeutics’ current full-year earnings is ($1.19) per share.

Other analysts have also recently issued reports about the company. HC Wainwright restated a “buy” rating and issued a $13.00 target price on shares of Tango Therapeutics in a report on Friday, November 8th. B. Riley cut their price objective on shares of Tango Therapeutics from $16.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, November 11th. Finally, Guggenheim decreased their target price on shares of Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, November 7th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $13.14.

Tango Therapeutics Price Performance

TNGX stock opened at $3.08 on Wednesday. Tango Therapeutics has a 1 year low of $2.59 and a 1 year high of $13.01. The firm has a market capitalization of $330.85 million, a PE ratio of -2.61 and a beta of 0.81. The business has a 50 day simple moving average of $3.31 and a 200-day simple moving average of $6.64.

Institutional Investors Weigh In On Tango Therapeutics

A number of hedge funds have recently added to or reduced their stakes in TNGX. Barclays PLC increased its position in shares of Tango Therapeutics by 78.3% during the third quarter. Barclays PLC now owns 126,281 shares of the company’s stock worth $972,000 after acquiring an additional 55,470 shares during the period. Geode Capital Management LLC increased its holdings in Tango Therapeutics by 11.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,368,262 shares of the company’s stock worth $10,538,000 after purchasing an additional 142,710 shares during the period. XTX Topco Ltd raised its position in Tango Therapeutics by 340.1% in the 3rd quarter. XTX Topco Ltd now owns 44,191 shares of the company’s stock valued at $340,000 after purchasing an additional 34,150 shares in the last quarter. Sphera Funds Management LTD. purchased a new position in shares of Tango Therapeutics in the 3rd quarter valued at about $385,000. Finally, State Street Corp boosted its stake in shares of Tango Therapeutics by 26.8% in the 3rd quarter. State Street Corp now owns 2,318,208 shares of the company’s stock valued at $17,850,000 after buying an additional 489,949 shares during the period. 78.99% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, insider Boxer Capital Management, Llc sold 3,080,000 shares of the stock in a transaction dated Wednesday, November 6th. The stock was sold at an average price of $3.14, for a total transaction of $9,671,200.00. Following the transaction, the insider now owns 3,610,642 shares of the company’s stock, valued at approximately $11,337,415.88. This represents a 46.03 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mace Rothenberg bought 10,000 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were purchased at an average price of $3.78 per share, with a total value of $37,800.00. Following the completion of the acquisition, the director now directly owns 31,250 shares in the company, valued at $118,125. This trade represents a 47.06 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 6.30% of the stock is currently owned by corporate insiders.

About Tango Therapeutics

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.